Juan-Manuel Anaya, MD, PhD

JCP
Vortioxetine for Cognitive Impairment in MDD Post-COVID
Original Research

May 5, 2025

Measures of cognitive function and depressive symptoms improved to a greater extent with vortioxetine than with escitalopram or sertraline in post-COVID syndrome participants with MDD.
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe